CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.
Date: Monday, October 5, 2020
Time: 11:00 – 11:25 AM Eastern Time
Location: Virtual Webcast
The presentation will be available for live streaming via https://wsw.com/webcast/chard6/xcur/1881648.
Replays of the webcast will be available on Exicure’s website for 30 days following the webcast.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at www.exicuretx.com.